These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 17237831)

  • 21. [Diabetes mellitus and cardiovascular diseases].
    Xiao XH
    Zhongguo Zhong Xi Yi Jie He Za Zhi; 2007 Aug; 27(8):678-9. PubMed ID: 17879524
    [No Abstract]   [Full Text] [Related]  

  • 22. Lipid screening and cardiovascular health in childhood.
    Daniels SR; Greer FR;
    Pediatrics; 2008 Jul; 122(1):198-208. PubMed ID: 18596007
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Hyperlipidaemia and cardiovascular disease: nonfasting triglycerides gain momentum--but nothing changes on the metabolic syndrome front.
    Dominiczak MH
    Curr Opin Lipidol; 2008 Jun; 19(3):326-7. PubMed ID: 18460927
    [No Abstract]   [Full Text] [Related]  

  • 24. Search and rescue for hypotheses surviving AIM-HIGH, the niacin therapy earthquake: still problematic after the primary publication.
    Brinton EA
    J Clin Lipidol; 2012; 6(4):312-7. PubMed ID: 22836067
    [No Abstract]   [Full Text] [Related]  

  • 25. Classical cardiovascular risk factors according to fasting plasma glucose levels.
    Martinez-Hervas S; Romero P; Hevilla EB; Real JT; Priego A; Martin-Moreno JM; Carmena R; Ascaso JF
    Eur J Intern Med; 2008 May; 19(3):209-13. PubMed ID: 18395166
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Unmet needs in controlling metabolic disease.
    Haffner SM
    Rev Cardiovasc Med; 2007; 8 Suppl 4():S17-24. PubMed ID: 17934390
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Solvay addresses unmet needs in the management of hypertensive patients with cardiometabolic and lipid disorders.
    Cardiovasc J Afr; 2009; 20(1):73-4. PubMed ID: 19287821
    [No Abstract]   [Full Text] [Related]  

  • 28. Effect of metabolic syndrome or type II diabetes mellitus on the occurrence of recurrent vascular events in hypertensive patients.
    Vlek AL; van der Graaf Y; Spiering W; Visseren FL;
    J Hum Hypertens; 2008 May; 22(5):358-65. PubMed ID: 18273039
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Metabolic syndrome, definitions and physiopathology].
    Monnier L; Bénichou M
    Soins; 2004 Apr; (684 Pt 2):4-7. PubMed ID: 15151084
    [No Abstract]   [Full Text] [Related]  

  • 30. The metabolic syndrome in polycystic ovary syndrome.
    Essah PA; Wickham EP; Nestler JE
    Clin Obstet Gynecol; 2007 Mar; 50(1):205-25. PubMed ID: 17304037
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Metabolic syndrome as a precursor of diabetes mellitus type 2 and cardiovascular diseases].
    Shestakova MV; Butrova SA; Sukhareva OIu
    Ter Arkh; 2007; 79(10):5-8. PubMed ID: 18154136
    [No Abstract]   [Full Text] [Related]  

  • 32. The appropriateness of nicotinic acid derivative use in patients with the metabolic syndrome: insights from the ARBITER 2 study.
    Al-Shaer MH; Jerome WP
    Am J Cardiol; 2006 Jul; 98(2):275-6. PubMed ID: 16828609
    [No Abstract]   [Full Text] [Related]  

  • 33. Is the concept of 'cardiometabolic risk' more useful than 'metabolic syndrome'?
    Koshiyama H; Taniguchi A; Inagaki N; Seino Y
    Diabet Med; 2007 May; 24(5):571. PubMed ID: 17470194
    [No Abstract]   [Full Text] [Related]  

  • 34. Mediterranean diet and metabolic diseases.
    Giugliano D; Esposito K
    Curr Opin Lipidol; 2008 Feb; 19(1):63-8. PubMed ID: 18196989
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Frequency of metabolic syndrome among hemodialysis patients according to NCEP-ATP III and IDF definitions.
    Ucar E; Huzmeli C; Guven O; Savas N; Gullu M; Asilyoruk S; Kuvandik C; Temizkan A; Kuvandik G
    Ren Fail; 2009; 31(3):221-8. PubMed ID: 19288328
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Increased total and high-molecular weight adiponectin after extended-release niacin.
    Plaisance EP; Grandjean PW; Brunson BL; Judd RL
    Metabolism; 2008 Mar; 57(3):404-9. PubMed ID: 18249215
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clinical significance of recent lipid trials on reducing risk in patients with type 2 diabetes mellitus.
    Jones PH
    Am J Cardiol; 2007 Feb; 99(4A):133B-140B. PubMed ID: 17307065
    [TBL] [Abstract][Full Text] [Related]  

  • 38. "K-ration". Diabetes and cardiovascular risk.
    Gottlieb SH
    Diabetes Forecast; 2002 Feb; 55(2):44-6. PubMed ID: 14959668
    [No Abstract]   [Full Text] [Related]  

  • 39. [Metabolic syndrome is under fire. International dispute about the risk factor complex's scientific basis].
    Nilsson PM; Fagerberg B
    Lakartidningen; 2005 Oct 31-Nov 6; 102(44):3202-3. PubMed ID: 16329449
    [No Abstract]   [Full Text] [Related]  

  • 40. Impact of insulin resistance on risk of type 2 diabetes and cardiovascular disease in people with metabolic syndrome.
    Meigs JB; Rutter MK; Sullivan LM; Fox CS; D'Agostino RB; Wilson PW
    Diabetes Care; 2007 May; 30(5):1219-25. PubMed ID: 17259468
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.